Article
Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Clinical lung cancer - 1 Jul 2018
Takashima Yuta, Sakakibara-Konishi Jun, Hatanaka Yutaka, Hatanaka Kanako C, Ohhara Yoshihito, Oizumi Satoshi, Hida Yasuhiro, Kaga Kichizo, Kinoshita Ichiro, Dosaka-Akita Hirotoshi, Matsuno Yoshihiro, Nishimura Masaharu
Abstract excerpt
BACKGROUND: Approximately 20% to 30% of non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-activating mutations are not responsive to EGFR tyrosine kinase inhibitors (TKIs). Although primary resistance to EGFR-TKIs has been attributed to various genetic alterations, little is known about the clinical and immunopathologic features of patients with primary resistance. The tumor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.